



Crossref



Crossmark (Metadata +)

Kirsty Meddings
Product Manager
@kmeddings

MedComms Networking Event, 4th January 2017



< Previous Article

Volume 388, No. 10063, p2997-3005, 17 December 2016

Next Article >

Access this article on [ScienceDirect](#)

Articles

Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial

Prof John F R Robertson, MD[†], Prof Igor M Bondarenko, PhD, Ekaterina Trishkina, PhD, Mikhail Dvorkin, MD, Prof Lawrence Panasci, MD, Alexey Manikhas, MD, Yaroslav Shparyk, PhD, Servando Cardona-Huerta, PhD, Kwok-Leung Cheung, MD, Manuel Jesus Philco-Salas, MD, Manuel Ruiz-Borrego, MD, Prof Zhimin Shao, MD, Prof Shinzaburo Noguchi, PhD, Jacqui Rowbottom, MSc, Mary Stuart, MD, Lynda M Grinsted, MSc, Mehdi Fazal, MD, Prof Matthew J Ellis, PhD[†]

[†] Contributed equally to this article

Published: 28 November 2016

Altmetric 78

DOI: [http://dx.doi.org/10.1016/S0140-6736\(16\)32389-3](http://dx.doi.org/10.1016/S0140-6736(16)32389-3)

CrossMark



Article Info

This article can be found in the following collections: [Breast cancer](#)

Article Options

- PDF (461 KB)
- Download Images(.ppt)
- Email Article
- Add to My Reading List
- Export Citation
- Create Citation Alert
- Cited by in Scopus (0)
- Request Permissions

Linked Articles

COMMENT
[Metastatic breast cancer: focus on endocrine sensitivity](#)

Popular Articles

Public health

Shape of the association between income and mortality: a cohort study of Denmark, Finland, Norway and Sweden in 1995 and 2003

Laust H Mortensen¹, Johan Rehnberg^{2,3}, Espen Dahl⁴, Finn Diderichsen¹, Jon Ivar Elstad⁵, Pekka Martikainen^{6,2,7}, David Rehkopf⁸, Lasse Tarkiainen⁶, Johan Fritzell³

[+ Author Affiliations](#)

Correspondence to

Johan Rehnberg; johan.rehnberg@ki.se

Received 29 December 2015

Revised 1 August 2016

Accepted 5 August 2016

Published 23 December 2016

Abstract

Objectives Prior work has examined the shape of the income–mortality association, but work has not compared gradients between countries. In this study, we focus on changes over time in the shape of income–mortality gradients for 4 Nordic countries during a period of rising income inequality. Context and time differentials in shape imply that the relationship between income and mortality is not fixed.

Setting Population-based cohort study of Denmark, Finland, Norway and Sweden.

Participants We collected data on individuals aged 25 or more in 1995 (n=12.98 million individuals, 0.84 million deaths) and 2003 (n=13.08 million individuals, 0.90 million deaths). We then examined the household size equivalised disposable income at the baseline year in relation to the rate of mortality in the following 5 years.

Results A steep income gradient in mortality in men and women across all age groups except the oldest old in Denmark, Finland, Norway and Sweden. From the 1990s to 2000s mortality dropped, but generally more so in the upper part of the income distribution than in the lower part. As a consequence, the shape of the income gradient in mortality changed. The shift in the shape of the association was similar in all 4 countries.

Conclusions A non-linear gradient exists between income and mortality in most cases and because of a more rapid mortality decline among those with high income the income gradient has become steeper over time.

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>



This Article

- Abstract
- Full text
- PDF
- Previous versions
- Review history

Services

- Email this link to a friend
- Alert me when this article is cited
- Alert me if a correction is posted
- Alert me when eletters are published
- Article Usage Statistics
- Similar articles in this journal
- Similar articles in PubMed
- Add article to my folders
- Download to citation manager
- Request permissions
- Add to portfolio

Responses

- Submit a response
- No responses published

Google Scholar

PubMed

Related Content

- Epidemiology
- Occupational and environmental medicine
- Public health

Social bookmarking

Podcasts

Most read

Blog

- UK research spend in 2008 and 2012: comparing stroke, cancer, coronary heart disease and dementia (19 May 2015)
- Impact of the urgent care telephone service NHS 111 pilot sites (21 Oct 2013)
- Prevalence and incidence rates of autism in the UK (8 Oct 2013)

Login via your home organisation

Recommend to your Institution

Register to receive email alerts



3 days of ideas, innovation and inspiration

26-28 April 2017
London

Early Bird ends
30 January 2017

[BOOK NOW](#)



BMJ Careers

Consultant Urological Surgeon

Select ▼

Please enter the search term



Advanced

[Home](#) >> [Journals](#) >> [Programme Grants for Applied Research](#) >> [Volume 4](#) >> [Issue 19](#)

Journals

Efficacy and
Mechanism Evaluation

Health Services and
Delivery Research

Health Technology
Assessment

Programme Grants for
Applied Research

Public Health Research

Safer delivery of surgical services: a programme of controlled before-and-after intervention studies with pre-planned pooled data analysis

The study found that the effects on team performance of single interventions employing lean, teamwork training or standard operating procedures were inconsistent. A combination of teamwork training plus systems improvement training appears more effective in improving team performance than either approach alone. Combining all three strategies did not increase the percentage of successful projects.

[McCulloch P](#), [Morgan L](#), [Flynn L](#), [Rivero-Arias O](#), [Martin G](#), [Collins G](#) & [New S](#).

► [Detailed Author information](#)

Programme Grants for Applied Research Volume: 4, Issue:19, Published in December 2016

<https://dx.doi.org/10.3310/pgfar04190>

Citation: McCulloch P, Morgan L, Flynn L, Rivero-Arias, Martin G, Collins G, *et al*. Safer delivery of surgical services: a programme of controlled before-and-after intervention studies with pre-planned pooled data analysis. *Programme Grants Appl Res* 2016;4(19)

Check for updates

Toolkit

[Download report PDF](#)

[Print](#)

[Download report documents](#)

[Alerts & updates](#)

[Purchase hard copy](#)

[Responses to this report\(0\)](#)

[Permissions information](#)

[VIEW PROJECT](#)

Share








 OPEN ACCESS  PEER-REVIEWED

RESEARCH ARTICLE

IL-7 Receptor Mutations and Steroid Resistance in Pediatric T cell Acute Lymphoblastic Leukemia: A Genome Sequencing Study

Yunlei Li , Jessica G. C. A. M. Buijs-Gladdines , Kirsten Canté-Barrett, Andrew P. Stubbs, Eric M. Vroegindewij, Willem K. Smits, Ronald van Marion, Winand N. M. Dinjens, Martin Horstmann, Roland P. Kuiper, Rogier C. Buijsman, Guido J. R. Zaman, Peter J. van der Spek, Rob Pieters, Jules P. P. Meijerink 

Published: December 20, 2016 • <http://dx.doi.org/10.1371/journal.pmed.1002200>

0 Save	0 Citation
2,070 View	11 Share

Article	Authors	Metrics	Comments	Related Content
----------------	----------------	----------------	-----------------	------------------------

[Download PDF](#) 

[Print](#) [Share](#)

Abstract

[Author Summary](#)

Abstract

 Check for updates

Crossmark

A button and a set of metadata that informs readers about-

- Publication status (current, updated, retracted)
- Funding behind the research
- Authors' ORCIDs
- Publication history
- Rights or licensing information
- And much more...

Publication status



erratum
corrigendum
correction
withdrawal
retraction
new edition
expression of concern
partial retraction
removal
addendum
clarification

The Chilling Effect: How Do Researchers React to Controversy?

Joanna Kempner*

Rutgers University, Department of Sociology and Institute for Health, Health Care Policy and Aging Research, New Brunswick, New Jersey, United States of America

Funding: This research was supported by the Robert Wood Johnson Foundation. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Competing Interests: The author has declared that no competing interests exist.

Academic Editor: Peter Singer, University of Toronto, Canada

Citation: Kempner J (2008) The chilling effect: How do researchers react to controversy? PLoS Med 5(11): e222. doi:10.1371/journal.pmed.0050222

ABSTRACT

Background

Can political controversy have a “chilling effect” on the production of new science? This is a timely concern, given how often American politicians are accused of undermining science for political purposes. Yet little is known about how scientists react to these kinds of controversies.

Methods and Findings

Drawing on interview ($n = 30$) and survey data ($n = 82$), this study examines the reactions of scientists whose National Institutes of Health (NIH)-funded grants were implicated in a highly publicized political controversy. Critics charged that these grants were “a waste of taxpayer money.” The NIH defended each grant and no funding was rescinded. Nevertheless, this study finds that many of the scientists whose grants were criticized now engage in self-censorship. About half of the sample said that they now remove potentially controversial words from their



IUCrJ

ISSN 2052-2525

CHEMISTRY | CRYSTENG

Keywords: Editorial; crystal engineering.

Crystal engineering and IUCrJ

Gautam R. Desiraju*

Solid State and Structural Chemistry Unit, Indian Institute of Science, Bangalore 560 012, India. *Correspondence e-mail: gautam.desiraju@gmail.com

Crystal engineering has grown over time, with its practitioners now seeking specific answers to specialized questions. How does a molecular crystal nucleate and then grow? Can its structure be predicted computationally? Can one design a crystal structure with knowledge-based inputs? Can a crystal structure be considered as a collection of modular entities which represent its microcosms? What properties are characteristic of the crystal as a whole rather than of its constituent molecules? Can these properties be designed and is property design different from structure design? Can one predict if a given compound will have polymorphs and pseudopolymorphs? Can one design the structures of multi-component crystals in which each component is a solid when taken separately under ambient conditions? All these issues connect through the structural landscape of crystals and the exploration of this landscape, that is crystallization. The subject of crystal engineering covers not only purely organic solids but also organometallics and more



Document is current

Any future updates will be listed below

Crystal engineering and IUCrJ

Crossref DOI link: <https://doi.org/10.1107/s2052252515024100>

Published: 2016-01-01

Update policy: https://doi.org/10.1107/cm_01

› Authors

› More Information

ORIGINAL RESEARCH ARTICLE

Front. Bioeng. Biotechnol., 20 January 2016 | <http://dx.doi.org/10.3389/fbioe.2016.00001>



Voice Pathology Detection Using Modulation Spectrum-Optimized Metrics


 **Laureano Moro-Velázquez***,  **Jorge Andrés Gómez-García** and  **Juan Ignacio Godino-Llorente**

Center for Biomedical Technology, Universidad Politécnica de Madrid, Madrid, Spain

There exist many acoustic parameters employed for pathological assessment tasks, which have served as tools for clinicians to distinguish between normophonic and pathological voices. However, many of these parameters require an appropriate tuning in order to maximize its efficiency. In this work, a group of new and already proposed modulation spectrum (MS) metrics are optimized considering different time and frequency ranges pursuing the maximization of efficiency for the detection of pathological voices. The optimization of the metrics is performed simultaneously in two different voice databases in order to identify what tuning ranges produce a better generalization. The

CrossMark



 **Updates are available**
Corrigendum dated 2016-08-24

Click to view Corrigendum:
<https://doi.org/10.3389/fbioe.2016.00067>

Voice Pathology Detection Using Modulation Spectrum-Optimized Metrics

Crossref DOI link: <https://doi.org/10.3389/fbioe.2016.00001>

Published:

Update policy: <https://doi.org/10.3389/crossmark-policy>

> Authors



[About CrossMark](#)



L RESEARCH AR
eng. Biotechnol.

ce Pat
pectrum

reano Moro-V
r Biomedical Tec

xist many ac
as tools for cl
er, many of th

cy. In this work, a group of new and already proposed modulation spectrum (MS) metrics
imized considering different time and frequency ranges pursuing the maximization of
er for the detection of pathological voices. The optimization of the metrics is performed


RESEARCH TOPIC
tions in biomedin


ulation

Godino-Llorent

which have
voices.
imize its



BUY ARTICLE 



Cloning, expression, crystallization and preliminary X-ray crystallographic analysis of aspartyl aminopeptidase from the *apeB* gene of *Pseudomonas aeruginosa*

S. Natarajan and R. Mathews

Aminopeptidases (APs) are a group of exopeptidases that catalyze the removal of amino acids from the N-termini of proteins and peptides. The APs are ubiquitous in nature and are of critical biological and medical importance because of their key role in protein degradation. *Pseudomonas aeruginosa* aspartyl aminopeptidase (PaAAP), which is encoded by the *apeB* gene, was expressed in *Escherichia coli*, purified and crystallized using the microbatch method. A preliminary structural study has been performed using the X-ray crystallographic method. The PaAAP crystal diffracted to 2.0 Å resolution and belonged to the rhombohedral space group *H3*, with unit-cell parameters $a = b = 133.6$, $c = 321.2$. The unit-cell volume of the crystal is compatible with the presence of four monomers in the asymmetric unit, with a corresponding Matthews coefficient V_M of 2.95 Å³ Da⁻¹ and a solvent content of 58.3%.



Keywords: *Pseudomonas aeruginosa*; aspartyl aminopeptidase.

[Read article](#)

[Correction](#)

[Similar articles](#)

search IUCr Jo

ve edito

IZATION COM

(12). F68, 20

/10.1107/S17

BUY ARTICLE

analysis

S. Nata

Aminop

from the

critical b

Pseudor

express

study ha

resolutio

321.2. 7

unit, wit

Keywo

Read a

ollow Acta C

UCr Journals

The IU

GO

anced search

thods.

✕

Retraction

Retraction dated 2012-11-01

Click to view Retraction:
<https://doi.org/10.1107/s1744309112039875>

Cloning, expression, crystallization and preliminary X-ray crystallographic analysis of aspartyl aminopeptidase from the *heapeB* gene of *Pseudomonas aeruginosa*


Crossref DOI link: <https://doi.org/10.1107/s1744309111054388>

Published: 2012-02-01

Update policy: https://doi.org/10.1107/cm_01

> Authors

> More Information

 Crossref

[About CrossMark](#)

JEM Home » 2017 Archive » 1 January » 214 (1): 245

Article

Deubiquitinase USP13 maintains glioblastoma stem cells by antagonizing mediated Myc ubiquitination

 Xiaoguang Fang,  Wenchao Zhou,  Qiulian Wu,  Zhi Huang,  Yu Shi,  Kailin Yang,  Cong Chen,  Qi Xie, Stephen C. Mack, Xiuxing Wang,  Angel M. Carcaboso,  Gaoliang Ouyang,  Roger E. McLendon, Xiu-wu Bian, Jeremy N. Rich,  Shideng Bao

DOI: 10.1084/jem.20151673 | Published December 6, 2016



Article

Figures & Data

Info

Metrics

Abstract

 Download PDF PDF + Supp Data Citation Tools Alerts Permissions

Glioblastoma is the most lethal brain tumor and harbors glioma stem cells (GSCs) with potent



✓ Document is current

Any future updates will be listed below

Deubiquitinase USP13 maintains glioblastoma stem cells by antagonizing FBXL14-mediated Myc ubiquitination

Crossref DOI link: <https://doi.org/10.1084/jem.20151673>

Published: 2017-01

Update policy: <https://doi.org/10.1084/jem.crossmarkpolicy>



› Authors

› Funding

› License Information



Document is current

Any future updates will be listed below

Deubiquitinase USP13 maintains glioblastoma stem cells by antagonizing FBXL14-mediated Myc ubiquitination

Crossref DOI link: <https://doi.org/10.1084/jem.20151673>

Published: 2017-01

Update policy: <https://doi.org/10.1084/jem.crossmarkpolicy>

▼ **Authors**

Fang, Xiaoguang <http://orcid.org/0000-0002-3368-4133>

Zhou, Wenchao

Wu, Qiulian <http://orcid.org/0000-0002-2040-4577>

Huang, Zhi <http://orcid.org/0000-0002-8658-7732>

Shi, Yu <http://orcid.org/0000-0002-3380-4545>

Yang, Kailin <http://orcid.org/0000-0001-5968-6738>

Chen, Cong <http://orcid.org/0000-0001-6552-791X>

Xie, Qi <http://orcid.org/0000-0002-2370-2078>

Mack, Stephen C.

Wang, Xiuxing

Carcaboso, Angel M. <http://orcid.org/0000-0002-8485-426X>

Sloan, Andrew E. <http://orcid.org/0000-0001-9607-5063>

Ouyang, Gaoliang

Melander, Roger E. <http://orcid.org/0000-0001-6688-4588>



Document is current

Any future updates will be listed below

Deubiquitinase USP13 maintains glioblastoma stem cells by antagonizing FBXL14-mediated Myc ubiquitination

Crossref DOI link: <https://doi.org/10.1084/jem.20151673>

Published: 2017-01

Update policy: <https://doi.org/10.1084/jem.crossmarkpolicy>


> Authors

∨ Funding

Funding for this research was provided by:

National Institutes of Health (CA184090, NS091080, NS099175, S10OD018205)

> License Information





Document is current

Any future updates will be listed below

Deubiquitinase USP13 maintains glioblastoma stem cells by antagonizing FBXL14-mediated Myc ubiquitination

Crossref DOI link: <https://doi.org/10.1084/jem.20151673>

Published: 2017-01

Update policy: <https://doi.org/10.1084/jem.crossmarkpolicy>

› Authors

› Funding

▼ License Information

[Version of Record](#) valid from 2016-12-06

[Version of Record](#) valid from 2017-07-03



Any future updates will be listed below

Native valve disease in patients with non-valvular atrial fibrillation on warfarin or rivaroxaban

Crossref DOI link: <https://doi.org/10.1136/heartjnl-2015-308120>

Published: 2016-07-01

Update policy: <https://doi.org/10.1136/crossmarkpolicy>

› Authors

▼ Clinical Trials ^{BETA}

Clinical trials referenced in this document

› [nct00403767](#) at [ClinicalTrials.gov](#)



[About CrossMark](#)



Insights and opinion on the latest medical research, clinical practices, and developments in the field. [About this blog »](#)

On Medicine



Clinical trial data and articles linked for the first time

After years of hard work, linked clinical trials are here! It's now possible to link all published articles related to a clinical trial through the CrossMark dialogue box. Daniel Shanahan, Associate Publisher at BioMed Central explains more about it in this blog, originally [posted on the CrossRef website](#).



Daniel Shanahan

Associate Publisher at BioMed Central

Daniel has an MA in Natural Sciences and MSc in Experimental and Theoretical Physics from

CrossMark

▼ Clinical Trials ^{BETA}

Clinical trials referenced in this document:

▼ nct00403767 at ClinicalTrials.gov

Documents that mention this clinical trial

Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF)

[https://doi.org/10.1016/s0140-6736\(14\)61836-5](https://doi.org/10.1016/s0140-6736(14)61836-5)

Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: The Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial)

<https://doi.org/10.1016/j.ahj.2015.07.006>

Native valve disease in patients with non-valvular atrial fibrillation on warfarin or rivaroxaban (Post-results)

<https://doi.org/10.1136/heartjnl-2015-308120>


Blood pressure control and stroke or bleeding risk in



THE LANCET

Articles


Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF)

Jeffrey B Washam, Pharm D, Susanna R Stevens, MS, Yuliya Lokhnygina, PhD, Prof Jonathan L Halperin, MD, Prof Günter Breithardt, MD, Prof Daniel E Singer, MD, Prof Kenneth W Mahaffey, MD, Prof Graeme J Hankey, MD, Scott D Berkowitz, MD, Christopher C Nessel, MD, Prof Keith A A Fox, MB ChB, Prof Robert M Califf, MD, Jonathan P Piccini, MD, Dr Manesh R Patel, MD  for the ROCKET AF Steering Committee and Investigators

Published Online: 05 March 2015

 89

DOI: <http://dx.doi.org/10.1016/S0140-673> 



THE LANCET

Online First Current Issue All Issues


Search

< Previous Article

Volume

Articles

Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF)

Jeffrey B Washam, Pharm D, Susanna R Breithardt, MD, Prof Daniel E Singer, MD, Christopher C Nessel, MD, Prof Keetal Patel, MD  for the ROCKET AF Study Group

Published Online: 05 March 2015

CrossMark

▼ Clinical Trials ^{BETA}

Clinical trials referenced in this document:

▼ nct00403767 at ClinicalTrials.gov

Documents that mention this clinical trial

Digoxin use in patients with atrial fibrillation and adverse cardiovascular outcomes: a retrospective analysis of the Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF)

[https://doi.org/10.1016/s0140-6736\(14\)61836-5](https://doi.org/10.1016/s0140-6736(14)61836-5)

Efficacy and safety of rivaroxaban in patients with diabetes and nonvalvular atrial fibrillation: The Rivaroxaban Once-daily, Oral, Direct Factor Xa Inhibition Compared with Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF Trial)

<https://doi.org/10.1016/j.ahj.2015.07.006>

Native valve disease in patients with non-valvular atrial fibrillation on warfarin or rivaroxaban (Post-results)

Digoxin use in atr

▼ More Information

[Publication:](#) IUCrJ

[Content type:](#) research papers

Peer review

Peer reviewed: Yes

Review process: Single blind

Publication history

Received: 24 December 2015

Accepted: 18 February 2016

Published online: 9 March 2016

[Supplementary materials:](#) This article has supporting information

Copyright and licencing

[Copyright:](#) © 2016 Karol Nasset al.

[Licence:](#) Creative Commons Attribution (CC-BY)

Machine access

Crossref REST API

<http://api.crossref.org>





```
← → ↻ api.crossref.org/funders/10.13039/100000001/works

{
  status: "ok",
  message-type: "work-list",
  message-version: "1.0.0",
  - message: {
    - items: [
      - {
        subtitle: [ ],
        - subject: [
          "Atomic and Molecular Physics, and Optics"
        ],
        - issued: {
          - date-parts: [
            - [
              2013,
              9,
              9
            ]
          ]
        },
        score: 1,
        prefix: "http://id.crossref.org/prefix/10.1364",
        - author: [
          - {
            family: "Liu",
            given: "Xiaoze"
          },
          - {
            family: "Goldberg",
```

Reference lists




cite with
certainty

A Comprehensive Survey of Retracted Articles from the Scholarly Literature
Michael L. Grieneisen, Minghua Zhang

References

Abstract
Introduction
Materials and Methods
Results
Discussion
Supporting Information
Acknowledgments
Author Contributions
References
Reader Comments (1)
Media Coverage (0)
Figures

-  1. Cokol M, Iossifov I, Rodriguez-Esteban R, Rzhetsky A (2007) How many scientific papers should be retracted? *EMBO Rep* 8: 422–423. doi: 10.1038/sj.embor.7400970
[View Article](#) • [PubMed/NCBI](#) • [Google Scholar](#)
2. Steen RG (2011) Retractions in the medical literature: Who is responsible for scientific integrity? *AMWA J* 26: 2–8.
[View Article](#) • [PubMed/NCBI](#) • [Google Scholar](#)
-  3. Titus SL, Wells JA, Rhoades LJ (2008) Repairing research integrity. *Nature* 453: 980–982. doi: 10.1038/453980a
[View Article](#) • [PubMed/NCBI](#) • [Google Scholar](#)
4. Fanelli D (2009) How many scientists fabricate and falsify research? A systematic review and meta-analysis of survey data. *PLoS One* 4: e5738. doi: 10.1371/journal.pone.0005738
[View Article](#) • [PubMed/NCBI](#) • [Google Scholar](#)
-  5. Budd JM, Sievert ME, Schultz TR, Scoville C (1999) Effects of article retraction on citation and practice in medicine. *Bull Med Libr Assoc* 87: 437–443.
[View Article](#) • [PubMed/NCBI](#) • [Google Scholar](#)
6. Korpela KM (2010) How long does it take for the scientific literature to purge itself of fraudulent material? The Breuning case revisited. *Curr Med Res Opin* 26: 843–847. doi: 10.1185/03007991003603804
[View Article](#) • [PubMed/NCBI](#) • [Google Scholar](#)

Latest numbers

- 4.3 million Crossmark buttons
- 340 publishers
 - 15,000 journals
- 40,000 status updates
 - 1,500+ retractions
 - 40,000 corrections
- 2.3 million items with additional metadata



Thank you

kmeddings@crossref.org

[@kmeddings](#)

orcid.org/0000-0001-9205-2956

www.crossref.org

www.MedCommsNetworking.com

